These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 29701928)

  • 61. Impulse control disorders in patients with prolactinoma receiving dopamine agonist therapy: a prospective study with 1 year follow-up.
    Celik E; Ozkaya HM; Poyraz BC; Saglam T; Kadioglu P
    Endocrine; 2018 Dec; 62(3):692-700. PubMed ID: 30206771
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Managing impulse control behaviours in Parkinson's disease: practical guidelines.
    Macphee GJ; Chaudhuri KR; David AS; Worth P; Wood B
    Br J Hosp Med (Lond); 2013 Mar; 74(3):160-6. PubMed ID: 23665786
    [No Abstract]   [Full Text] [Related]  

  • 63. Mental disturbances during bromocriptine and lergotrile treatment of Parkinson's disease.
    Serby M; Angrist B; Lieberman A
    Am J Psychiatry; 1978 Oct; 135(10):1227-9. PubMed ID: 29497
    [No Abstract]   [Full Text] [Related]  

  • 64. Dopamine dysregulation syndrome in non-Parkinson's disease patients: a systematic review.
    Cartoon J; Ramalingam J
    Australas Psychiatry; 2019 Oct; 27(5):456-461. PubMed ID: 31032624
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Partial dopamine agonist-induced pathological gambling and impulse-control deficit on low-dose aripiprazole.
    Peterson E; Forlano R
    Australas Psychiatry; 2017 Dec; 25(6):614-616. PubMed ID: 28696131
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Dopamine D3 receptor Ser9Gly variant is associated with impulse control disorders in Parkinson's disease patients.
    Bhattacharjee S; Talbot JG; Vijayashankar P
    Parkinsonism Relat Disord; 2017 Jan; 34():69-70. PubMed ID: 27802909
    [No Abstract]   [Full Text] [Related]  

  • 67. Impulse control disorders in Parkinson's disease: a hard-turning point.
    Martinez-Castrillo JC
    J Neurol Neurosurg Psychiatry; 2019 Jan; 90(1):2. PubMed ID: 30361297
    [No Abstract]   [Full Text] [Related]  

  • 68. Valproate as a treatment for dopamine dysregulation syndrome (DDS) in Parkinson's disease.
    Sriram A; Ward HE; Hassan A; Iyer S; Foote KD; Rodriguez RL; McFarland NR; Okun MS
    J Neurol; 2013 Feb; 260(2):521-7. PubMed ID: 23007193
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Orally disintegrating selegiline in Parkinson patients with dopamine agonist-related adverse effects.
    Lyons KE; Friedman JH; Hermanowicz N; Isaacson SH; Hauser RA; Hersh BP; Silver DE; Tetrud JW; Elmer LW; Parashos SA; Struck LK; Lew MF; Pahwa R
    Clin Neuropharmacol; 2010; 33(1):5-10. PubMed ID: 19855267
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Reports of pathological gambling, hypersexuality, and compulsive shopping associated with dopamine receptor agonist drugs.
    Moore TJ; Glenmullen J; Mattison DR
    JAMA Intern Med; 2014 Dec; 174(12):1930-3. PubMed ID: 25329919
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Does response inhibition have pre- and postdiagnostic utility in Parkinson's disease?
    MacDonald HJ; Byblow WD
    J Mot Behav; 2015; 47(1):29-45. PubMed ID: 25575221
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Markers of impaired motor and cognitive volition in Parkinson's disease: Correlates of dopamine dysregulation syndrome, impulse control disorder, and dyskinesias.
    Hinkle JT; Perepezko K; Rosenthal LS; Mills KA; Pantelyat A; Mari Z; Butala A; Moukheiber E; Dawson TM; Pontone GM
    Parkinsonism Relat Disord; 2018 Aug; 53():108-109. PubMed ID: 29753604
    [No Abstract]   [Full Text] [Related]  

  • 73. [Stealing as an Impulse Control Disorder Associated with Pramipexole - A Case Report from Forensic Psychiatric Practice].
    Clemm von Hohenberg C; Dreßing H
    Psychiatr Prax; 2017 Apr; 44(3):172-174. PubMed ID: 28399600
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Dopamine agonist withdrawal syndrome: A comprehensive review.
    Yu XX; Fernandez HH
    J Neurol Sci; 2017 Mar; 374():53-55. PubMed ID: 28104232
    [TBL] [Abstract][Full Text] [Related]  

  • 75. New onset heightened interest or drive for gambling, shopping, eating or sexual activity in patients with Parkinson's disease: the role of dopamine agonist treatment and age at motor symptoms onset.
    Giladi N; Weitzman N; Schreiber S; Shabtai H; Peretz C
    J Psychopharmacol; 2007 Jul; 21(5):501-6. PubMed ID: 17446202
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Treating prolactinomas with dopamine agonists: always worth the gamble?
    Noronha S; Stokes V; Karavitaki N; Grossman A
    Endocrine; 2016 Feb; 51(2):205-10. PubMed ID: 26336835
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Effects of dopamine agonist dose and gender on the prognosis of impulse control disorders in Parkinson's disease.
    Joutsa J; Martikainen K; Vahlberg T; Kaasinen V
    Parkinsonism Relat Disord; 2012 Dec; 18(10):1079-83. PubMed ID: 22784693
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Management of impulse control disorders in Parkinson's disease.
    Zhang S; Dissanayaka NN; Dawson A; O'Sullivan JD; Mosley P; Hall W; Carter A
    Int Psychogeriatr; 2016 Oct; 28(10):1597-614. PubMed ID: 27373317
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Duration of L-dopa and dopamine agonist monotherapy in Parkinson's disease.
    Nissen T; Newman EJ; Grosset KA; Daghem M; Pal G; Stewart M; Odin P; Macphee GJ; Grosset DG
    Scott Med J; 2012 Nov; 57(4):217-20. PubMed ID: 23002158
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Risk factors for pathologic gambling and other compulsions among Parkinson's disease patients taking dopamine agonists.
    Singh A; Kandimala G; Dewey RB; O'Suilleabhain P
    J Clin Neurosci; 2007 Dec; 14(12):1178-81. PubMed ID: 17720504
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.